COMMUNIQUÉS West-GlobeNewswire

Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
07/05/2025
BJT-188 demonstrated liver-specific potency with minimal exposure to other tissues The data are being presented at the European Association for the Study of the Liver (EASL) Congress 2025 REDWOOD CITY, Calif., May 07, [...]
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
07/05/2025
Additional late-breaking data suggests up to twice as many patients treated with IQIRVO ® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatment IQIRVO dual PPAR α / δ [...]
De nouvelles données issues d’analyses exploratoires soulignent l’impact d’IQIRVO® (élafibranor) sur la fatigue et mettent en lumière son mécanisme d’action sur l’inflammation et les symptômes associés à la cholangite biliaire primitive
07/05/2025
D’autres données nouvelles suggèrent que jusqu’à deux fois plus de patients traités avec IQIRVO ® ont constaté une amélioration cliniquement significative de la fatigue par rapport au placebo après 52 semaines de [...]
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
07/05/2025
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher Edinburgh, UK, 7 May 2025 - Trogenix Ltd (“Trogenix”), a pioneering [...]
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
07/05/2025
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% at constant exchange rates (CER) to DKK 38.8 billion. Sales in US Operations [...]
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
07/05/2025
Press Release CROSSJECT provides updates on the EUA filing of ZEPIZURE® CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the [...]
CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE®
07/05/2025
Communiqué de presse CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE® CROSSJECT et son partenaire EUROFINS ont achevé avec succès le remplissage aseptique de tous les lots [...]
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
07/05/2025
Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024 Cash and cash equivalents of €153.0 million at end of March 2025 Further clinical and regulatory progress 2025 financial outlook [...]
Valneva publie ses résultats financiers du premier trimestre 2025 et fait un point sur son activité
07/05/2025
Chiffre d’affaires de 49,2 millions d’euros contre 32,8 millions d’euros au premier trimestre 2024 Trésorerie et équivalents de trésorerie de 153,0 millions d’euros à fin mars 2025 Poursuite des avancées cliniques et [...]
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
07/05/2025
First results of SCENESSE® study expected in 2H 2026 Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved Randomised trial, 20-week treatment protocol [...]
PrimeBiome Reviews Consumer Reports: Critical Complaints & Customer Reviews Exposed!
07/05/2025
ANCHORAGE, Alaska, May 07, 2025 (GLOBE NEWSWIRE) -- PrimeBiome is a natural skin and gut health formula that has been gaining immense popularity in the market. As per the claims of the manufacturers, this formula is [...]
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
07/05/2025
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform [...]
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
07/05/2025
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and [...]
Dogecoin Cash, Inc. Confirms Stock Dividend Record and Payment Dates; FINRA Publication Completed
07/05/2025
MESQUITE, NV, May 06, 2025 (GLOBE NEWSWIRE) -- March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the [...]
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
07/05/2025
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 [...]
Dunham House Breaks Ground on Transformational Housing for Combat-Wounded Veterans
06/05/2025
OMAHA, Neb., May 06, 2025 (GLOBE NEWSWIRE) -- Between 2000 and 2019, the Defense and Veterans Brain Injury Center reported nearly 414,000 service members worldwide sustained a traumatic brain injury. In the same period [...]
WeightWatchers Takes Strategic Action to Eliminate $1.15 Billion of Debt, Strengthening Financial Position for Long-Term Growth and Profitability
06/05/2025
Operations continue with no impact to its more than three million members worldwide Positions the Company to execute its transformation strategy, focused on enhancing its digital and member experience and expanding its [...]
Extendicare Announces 2025 First Quarter Results
06/05/2025
MARKHAM, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2025. First Quarter 2025 Highlights Adjusted [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2025 Financial Results on May 8, 2025
06/05/2025
FREDERICK, Md., May 06, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]

Pages